Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 9—September 2026

Research

Posttuberculosis Consequences on Tuberculosis Prevention Effectiveness and Cost-effectiveness among New Immigrants, Canada

Aotikuer Ainiwaer, Aashna Uppal, Kevin Schwartzman, Kamila Romanowski, Sarah K. Brode, James C. Johnston, and Jonathon R. CampbellComments to Author 
Author affiliation: McGill University, Montreal, Quebec, Canada (A. Ainiwaer, K. Schwartzman, J.R. Campbell); University of Oxford, Oxford, UK (A. Uppal); Research Institute of the McGill University Health Centre, Montreal (K. Schwartzman, J.R. Campbell); McGill International TB Centre, Montreal (K. Schwartzman, J.R. Campbell); University of British Columbia, Vancouver, British Columbia, Canada (K. Romanowski, J.C. Johnston); British Columbia Centre for Disease Control, Vancouver (K. Romanowski, J.C. Johnston); University of Toronto, Toronto, Ontario, Canada (S.K. Brode); West Park Healthcare Centre, Toronto (S.K. Brode)

Main Article

Figure

PRCC for incremental net monetary benefit as drivers of cost-effectiveness of tuberculosis prevention among immigrants, Canada. Incremental net monetary benefit refers to the difference in net monetary benefit between the intervention and the status quo. In this analysis, parameters with more extreme positive PRCC estimates improve the incremental net monetary benefit as they increase. Parameters with more extreme negative PRCC estimates worsen the incremental net monetary benefit as they increase. Error bars indicate 95% uncertainty range. 4R, 4 months of rifampin treatment; PRCC, partial rank correlation coefficient; TB, tuberculosis; TPT, tuberculosis preventive treatment; TST, tuberculin skin test.

Figure. PRCC for incremental net monetary benefit as drivers of cost-effectiveness of tuberculosis prevention among immigrants, Canada. Incremental net monetary benefit refers to the difference in net monetary benefit between the intervention and the status quo. In this analysis, parameters with more extreme positive PRCC estimates improve the incremental net monetary benefit as they increase. Parameters with more extreme negative PRCC estimates worsen the incremental net monetary benefit as they increase. Error bars indicate 95% uncertainty range. 4R, 4 months of rifampin treatment; PRCC, partial rank correlation coefficient; TB, tuberculosis; TPT, tuberculosis preventive treatment; TST, tuberculin skin test.

Main Article

Page created: July 30, 2026
Page updated: August 17, 2026
Page reviewed: August 17, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external